ReCode Therapeutics
Main focus: Treatment of genetic diseases
Company stage: Pre-clinical
Diseases: Cystic fibrosis, genetic diseases
Genome editing tool: CRISPR
Funding stage: Private
Location: Menlo Park, CA, USA
Website: https://recodetx.com/
Pipeline: https://recodetx.com/pipeline/
ReCode Therapeutics is mainly focused on treating genetic diseases using its mRNA technologies. However, the company is also pursuring gene-editing modalities, which it is able to deliver using proprietary technologies. The company's lead gene-editing programmes have yet to be disclosed.